Home > Boards > US OTC > Medical - Equipment > Ozop Surgical Corp. (OZSC)

The exclusive License Agreement allows Ozop to sell

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
sharky Member Profile
Member Level 
Followed By 1,372
Posts 102,296
Boards Moderated 6
Alias Born 01/22/04
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2019 4:58:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/31/2019 4:39:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2019 4:14:19 PM
Information Statement - All Other (definitive) (def 14c) Edgar (US Regulatory) - 10/15/2019 8:02:20 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/7/2019 5:15:09 PM
Proxy Statement - Other Information (preliminary) (pre 14c) Edgar (US Regulatory) - 10/4/2019 4:14:27 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/2/2019 6:00:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/24/2019 4:02:22 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 9/19/2019 5:18:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/17/2019 8:07:03 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 9/16/2019 8:52:49 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/26/2019 9:04:41 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/23/2019 5:23:42 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/19/2019 2:49:08 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/15/2019 4:07:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2019 4:27:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/10/2019 5:14:24 PM
Information Statement - All Other (definitive) (def 14c) Edgar (US Regulatory) - 6/28/2019 10:35:02 AM
Proxy Statement - Other Information (preliminary) (pre 14c) Edgar (US Regulatory) - 6/14/2019 4:05:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2019 5:12:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/31/2019 4:48:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/22/2019 5:20:39 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 5:40:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/9/2019 5:12:37 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/2/2019 4:40:35 PM
sharky Member Level  Thursday, 10/17/19 12:14:21 PM
Re: None
Post # of 1612 
The exclusive License Agreement allows Ozop to sell SRI’s Swedge (patented, FDA approved pedicle screw system) technology and patent pending transition rod which has been shown to reduce contact pressure and stress shielding in the spine along with a unique pathway into the deformity market. OZOP will also gain access to a full product portfolio including 3D-printed, Peek and Carbon Fiber technology products.OZOP will be able to access the SRI network of distributors and hospital contracts through SRI whereby the OZOP product portfolio can be distributed along SRI branded product, with access to the existing and future distribution base. With its relationships with distributors outside of the SRI network, Ozop immediately plans to be able to add additional sales of SRI product, giving the Company a clear path to operating profit. As Ozop completes their development of their expandable cage in 2020, and other in development products, it would be a natural fit for many of the existing distributors to sell these Ozop products thru the existing SRI contracts as well as new contracts being immediately sought.

An additional benefit is OZOP will be able to reduce planned costs based by utilizing the SRI infrastructure, specifically, mandated FDA quality and inventory control standards and systems.

Bernie Bedor, founder, CEO and sixteen- year veteran of the medical device industry, stated: “This venture aligned with SRI’s philosophy that innovation doesn’t occur in a vacuum, but requires dedication, passionate and inventive engagement. What we have created is a strong demonstration of our commitment to creating a solution necessary for expanding our approach without inflating costs. The medical/device industry will be excited by Ozop’s objectives, and their continued recognition of SRI’s mission which is to support cost-effective patient care with innovative mechanical and biomechanical products.”

Michael Chermak, Chief Executive Officer of OZOP, commented, “This relationship allows us to focus on developing a sustainable revenue strategy while continuing to drive innovation that treats disorders of the spine. The combined efforts will rapidly accelerate the sales efforts already in place through Spinal Resources.”


$OZSC

Surrounded by thieves, lets fight our way out!


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist